Alternatives to H1

Leveraging AI and advanced analytics to drive innovation in healthcare and life sciences.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Quantum software company enabling breakthroughs in chemistry, materials science, and life sciences.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A global leader in clinical pharmacology and bioanalytical sciences.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

AI-powered patient-centric drug simulations to accelerate and de-risk drug development.

Cloud platform for secure sharing and analysis of real-world health data for life sciences.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Biotechnology company developing immuno-neurology therapies for neurodegenerative diseases.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

Pioneering vision restoration therapies for severe retinal degenerations.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Developing oral small molecule medicines for immunological and chronic diseases.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Developing first-in-class oral therapy for BK polyomavirus infections.

Immunotherapy company targeting oncology and autoimmune diseases.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Developing novel male contraceptives.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

A biopharmaceutical company focused on drug discovery and development.

Platform designed to cut cell and gene therapy production costs.

Advancing targeted alpha therapies.

Develops and distributes bioreactor technology for stem cell cultivation.

AI-enabled technology for cell biology research and biopharma development.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

Develops long-acting implantable and injectable therapies for opioid addiction and chronic pain.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Omec.ai is a life sciences startup focused on accelerating drug discovery and development through AI.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.

Accelerating medicine for the people who need it, prescribe it, and create it.

Discovering and developing first-in-class antibody therapeutics by identifying protective antibodies from disease-resilient individuals.

Developing novel therapeutics for inflammatory and hypoxic diseases.

Clinical-stage biotech company developing transformative cytokine therapies.

Venture philanthropy organization accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD).

A clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.

A global biotechnology company discovering, developing, manufacturing, and delivering innovative human therapeutics.